Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Update

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the target of a large growth in short interest in July. As of July 31st, there was short interest totaling 2,273,103 shares, a growth of 56.9% from the July 15th total of 1,448,757 shares. Based on an average daily volume of 835,918 shares, the days-to-cover ratio is currently 2.7 days. Currently, 3.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Nautilus Biotechnology currently has a consensus rating of “Hold” and an average target price of $4.00.

Insider Buying and Selling

In other news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total value of $11,750,000.00. Following the completion of the sale, the insider directly owned 971,885 shares of the company’s stock, valued at approximately $2,283,929.75. This trade represents a 83.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 41.10% of the company’s stock.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds have recently made changes to their positions in the stock. Garde Capital Inc. purchased a new stake in shares of Nautilus Biotechnology in the 4th quarter worth approximately $35,000. Hudson Bay Capital Management LP purchased a new position in Nautilus Biotechnology during the fourth quarter valued at $37,000. Qube Research & Technologies Ltd bought a new stake in Nautilus Biotechnology in the second quarter worth $45,000. Virtu Financial LLC boosted its holdings in Nautilus Biotechnology by 19.6% in the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after acquiring an additional 3,849 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. purchased a new stake in shares of Nautilus Biotechnology in the first quarter worth $48,000. 50.71% of the stock is owned by institutional investors.

Nautilus Biotechnology Price Performance

Shares of Nautilus Biotechnology stock opened at $0.88 on Tuesday. The company has a 50-day moving average of $1.65 and a 200 day moving average of $2.33. The firm has a market cap of $112.04 million, a price-to-earnings ratio of -1.96 and a beta of 0.87. Nautilus Biotechnology has a 1 year low of $0.62 and a 1 year high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings data on Tuesday, July 28th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.10 million.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.